Fore is a registration stage targeted oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers. The Company's lead asset plixorafenib (FORE8394; formerly PLX8394) is a V600 and non-V600 BRAF inhibitor rationally designed with a first-in-class mechanism to address treatment gaps from 1st¯and 2nd¯generation BRAF inhibitors.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
07/14/26	$67,400,000	Series D-2 Extension	3B Future Health Fund Axil Capital Cormorant Asset Management HBM Healthcare Investments LG Technology Ventures Medicxi Novartis Venture Funds OrbiMed Advisors Primer Ventures Samsung Ventures SR One Symbiosis TaiAx Wellington Management Windham Life Science Partners	undisclosed